
W Robert Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4092949/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clinical Cancer Informatics, 2022, , .	1.0	0
2	Reconciling outcomes for Black men with prostate cancer within and outside the Veterans Health Administration. Cancer, 2021, 127, 342-344.	2.0	7
3	Combination of Radiation Therapy andÂShort-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for MenÂWith High- and Intermediate-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1271-1278.	0.4	10
4	Gratitude Is the Attitude: Acknowledgments After 10 Years With Practical Radiation Oncology. Practical Radiation Oncology, 2021, 11, 1-2.	1.1	1
5	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE, 2021, 16, e0249123.	1.1	4
6	Unfilled Positions in the 2021 Radiation Oncology Match. Practical Radiation Oncology, 2021, 11, 323-324.	1.1	5
7	Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy In Patients with Prostate Cancer. Advances in Radiation Oncology, 2021, 7, 100805.	0.6	2
8	Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. BMJ Evidence-Based Medicine, 2021, 26, bmjebm-2020-111592.	1.7	0
9	Facilitating the Transition to Independent Radiation Oncology Practice Through a Resident-Led, Veterans Affairs Teaching Hospital Service. Practical Radiation Oncology, 2021, 11, 441-447.	1.1	2
10	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	2.8	16
11	Unfilled Positions in the 2020 Radiation Oncology Residency Match: No Longer an Isolated Event. Practical Radiation Oncology, 2020, 10, e307-e308.	1.1	22
12	Grateful Recognition of PRO Reviewer Apprentices and Reviewers of the Year. Practical Radiation Oncology, 2020, 10, 141.	1.1	0
13	Editor's Note. Practical Radiation Oncology, 2020, 10, 73.	1.1	0
14	What Can Journals Do to Increase the Reliability of Scientific Research?. Practical Radiation Oncology, 2020, 10, 139-140.	1.1	0
15	Radiation Biology for Radiation Oncology Residents: An Alternative View. Practical Radiation Oncology, 2019, 9, 504-505.	1.1	3
16	Protonâ€beam therapy after radical prostatectomy: Continued DVH idolatry?. Cancer, 2019, 125, 4136-4138.	2.0	2
17	A Call for Change in the ABR Initial Certification Examination in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2019, 104, 17-20.	0.4	22
18	The High Number of Unfilled Positions in the 2019 Radiation Oncology Residency Match: Temporary Variation or Indicator of Important Change?. Practical Radiation Oncology, 2019, 9, 300-302.	1.1	28

W ROBERT LEE

#	Article	IF	CITATIONS
19	Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results. Brachytherapy, 2019, 18, 426.	0.2	2
20	Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial Journal of Clinical Oncology, 2019, 37, 29-29.	0.8	2
21	Multi-institutional analysis of synchronous prostate and rectosigmoid cancers Journal of Clinical Oncology, 2019, 37, 33-33.	0.8	0
22	Thoughts on the American Board of Radiology Examinations and the resident experience in radiation oncology. Practical Radiation Oncology, 2018, 8, 298-301.	1,1	11
23	Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 383-390.	0.4	7
24	In recognition of the 2017 PRO reviewer apprentices. Practical Radiation Oncology, 2018, 8, 297.	1.1	0
25	Moderate hypofractionation for prostate cancer. Translational Andrology and Urology, 2018, 7, 321-329.	0.6	5
26	Scholarly Publishing and the Metric System. International Journal of Radiation Oncology Biology Physics, 2018, 101, 784-785.	0.4	1
27	Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer Journal of Clinical Oncology, 2018, 36, 11-11.	0.8	3
28	Effect of the Adoption of a Comprehensive Electronic Health Record on Graduate Medical Education: Perceptions of Faculty and Trainees. Southern Medical Journal, 2018, 111, 476-483.	0.3	3
29	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis Journal of Clinical Oncology, 2018, 36, 24-24.	0.8	0
30	Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 718-721.	0.4	13
31	Why the Aversion?. Journal of Graduate Medical Education, 2017, 9, 255-255.	0.6	0
32	A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer Journal of Clinical Oncology, 2017, 35, 67-67.	0.8	0
33	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy Journal of Clinical Oncology, 2017, 35, 9-9.	0.8	0
34	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy Journal of Clinical Oncology, 2017, 2017, 9-9.	0.8	0
35	Invited commentary on GETUG-AFU 16. Translational Andrology and Urology, 2016, 5, 958-960.	0.6	3
36	In regard to Wu and Vapiwala et al. International Journal of Radiation Oncology Biology Physics, 2016, 94. 858-859.	0.4	2

W ROBERT LEE

#	Article	IF	CITATIONS
37	Hypofractionation for prostate cancer: tested and proven. Lancet Oncology, The, 2016, 17, 1020-1022.	5.1	10
38	Six-Year Checkup: Narrowing the Scope of Practical Radiation Oncology. Practical Radiation Oncology, 2016, 6, 1-2.	1.1	1
39	NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer Journal of Clinical Oncology, 2016, 34, 1-1.	0.8	14
40	Seduced by technology?. Cancer, 2015, 121, 2300-2302.	2.0	0
41	Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. Journal of Palliative Medicine, 2015, 18, 933-939.	0.6	8
42	Practice patterns for peer review in radiation oncology. Practical Radiation Oncology, 2015, 5, 32-38.	1.1	53
43	External Beam Radiation Therapy for Clinically Localized Prostate Cancer. , 2015, , 731-742.		0
44	Reporting of Uncertainty at the 2013 Annual Meeting of the American Society for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2014, 89, 222-223.	0.4	1
45	Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Practical Radiation Oncology, 2014, 4, 187-191.	1.1	30
46	We Need Better Figures!. International Journal of Radiation Oncology Biology Physics, 2014, 88, 236.	0.4	4
47	Prostate Cancer and the Hypofractionation Hypothesis. Journal of Clinical Oncology, 2013, 31, 3849-3851.	0.8	28
48	Intensity-Modulated Radiotherapy. , 2013, , 749-759.		0
49	The development of oncology treatment guidelines: an analysis of the National Guidelines Clearinghouse. Practical Radiation Oncology, 2011, 1, 33-37.	1.1	0
50	We need better randomized comparison trials of prostate cancer. Cancer, 2010, 116, 270-272.	2.0	1
51	In Reply to Dr. Lawrence. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1276-1277.	0.4	0
52	Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy, 2009, 8, 191-196.	0.2	20
53	Extreme hypofractionation for prostate cancer. Expert Review of Anticancer Therapy, 2009, 9, 61-65.	1.1	16

1

W ROBERT LEE

#	Article	IF	CITATIONS
55	Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. Future Oncology, 2007, 3, 649-654.	1.1	3
56	Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy. Cancer, 2007, 109, 1506-1512.	2.0	56
57	Prostate brachytherapy: A descriptive analysis from CaPSURE. Brachytherapy, 2007, 6, 123-128.	0.2	4
58	Computer-Based Learning in Medical Education: A Critical View. Journal of the American College of Radiology, 2006, 3, 793-798.	0.9	15
59	Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology, 2006, 3, 534-535.	4.3	0
60	Lycopene Dietary Supplements and Prostate Cancer Treatment. Seminars in Preventive and Alternative Medicine, 2006, 2, 72-75.	0.1	0
61	Pretreatment serum prostate-specific antigen (PSA) level and PSA doubling times (PSADT) in black and white men with prostate cancer referred for radiation therapy. Radiation Oncology Investigations, 1996, 4, 135-139.	1.3	0
62	Radiation therapy following radical prostatectomy. Cancer, 1995, 75, 1909-1913.	2.0	6
63	External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990. Cancer, 1995, 75, 1972-1977.	2.0	37
64	T2-T3 carcinoma of the supraglottic larynx:A comparison of surgery and radiotherapy. Radiation Oncology Investigations, 1994, 2, 237-244.	1.3	4